We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

New Methods Detect Early Onset of Alzheimer's Disease

By LabMedica International staff writers
Posted on 28 Jul 2016
Print article
Image: The Quickplex SQ 120 plate reader for electrochemiluminescence analyses (Photo courtesy of Meso Scale Discovery).
Image: The Quickplex SQ 120 plate reader for electrochemiluminescence analyses (Photo courtesy of Meso Scale Discovery).
New methods to examine the brain and spinal fluid heighten the chance of early diagnosis of Alzheimer's disease and this may have important implications for early detection of the disease, the choice of drug treatment and the inclusion of patients in clinical trials.

It has become increasingly clear that, if the disease is to be treated successfully, it must be detected early, perhaps even before symptoms are evident. Thus, there is a great need for reliable diagnostic methods so that treatment to slow or prevent the disease can begin as early as possible.

Scientists at the Karolinska Institute (Solna, Sweden) and their colleagues studied a population consisted of 243 subjects for whom Pittsburgh compound B imaging positron emission tomography (PiB PET) data and cerebrospinal fluid (CSF) data and samples were available. These were collected across seven European academic centers belonging to the Biomarkers for Alzheimer’s and Parkinson’s Disease (BIOMARKAPD) initiative. In addition, 13 with normal cognition were recruited from relatives and carers of patients.

Apolipoprotein E (APOE) genotyping was performed in a subset of 106 subjects via polymerase chain reaction (PCR) of genomic DNA extracted from EDTA-anticoagulated blood. Subjects were classified as ϵ4 allele carriers or non-carriers. Amyloid-β42, total tau, and phosphorylated tau were measured using commercially available sandwich enzyme-linked immunosorbent assays (ELISAs) (INNOTEST, Fujirebio-Europe, Gent, Belgium). Meso Scale Discovery electrochemiluminescence analyses (MSD, Rockville, MD, USA) and a novel mass spectrometry method for amyloid-β42 and amyloid-β40 were also performed.

The scientists found that the best fit was achieved when the amyloid level in the brain was compared with the ratio between the levels of amyloid42 and amyloid40 in the spinal fluid. Given this finding, the team hypothesized that the forms of β-amyloid found in the brain and spinal fluid are not completely identical. While technical factors cannot be excluded outright as contributing to measured amyloid-β42 and amyloid-β40 levels in CSF assays, even when run in the same time and place, continued discordance using centrally re-analyzed samples suggests that biological factors are also at play.

Agneta K. Nordberg. MD, PhD, a professor and the study coordinator said, “Interestingly, there was also a difference between the values measured in the brain and spinal fluid in a smaller group of patients. This may justify that, in some unclear cases, the diagnosis should include an amyloid PET scan to complement the cerebrospinal fluid sample. These findings are also important because it is increasingly common to perform amyloid-PET studies upon the inclusion of patients in new drug studies.” The study was published on July 7, 2016, in the journal Brain.

Related Links:
Karolinska Institute
Fujirebio-Europe
Meso Scale Discovery
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.